Clinical Trial

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-04-10; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting 2025-12-04
Trial Details
NCT Number NCT06932562
Lead Sponsor European Myeloma Network B.V.
Collaborators: Regeneron Pharmaceuticals
Conditions Multiple Myeloma
Enrollment 1,000 participants
Start Date 2025-12-23
Primary Completion 2036-12 (estimated)
Study Completion 2036-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-25